00:51 , Jan 23, 2019 |  BC Extra  |  Politics & Policy

SCOTUS upholds lower court's ruling in Helsinn patent case

Biotech companies seeking R&D partners should file patents early for their inventions, in light of the U.S. Supreme Court's unanimous decision Tuesday saying some private sales of inventions qualify as prior art in patent litigation....
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
19:17 , Jun 2, 2017 |  BC Week In Review  |  Company News

Appeals court reverses opinion, invalidates Aloxi palonosetron patents from Helsinn

In early May, a federal appeals court invalidated U.S. Patent Nos. 7,947,724; 7,947,725; 7,960,424; and 8,598,219 from Helsinn Healthcare S.A. (Lugano, Switzerland) covering Aloxi palonosetron. The decision allows competition from a generic palonosetron product from...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Helsinn, Eisai sales and marketing update

Helsinn and Eisai said the American Society of Clinical Oncology (ASCO) has recognized Akynzeo netupitant /palonosetron as an option to prevent acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy regimens. Helsinn...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Helsinn, Dr. Reddy’s Laboratories Ltd. deal

Helsinn and Dr. Reddy’s settled patent litigation for Aloxi palonosetron in the U.S. Dr. Reddy’s will now be able to market a generic version of Aloxi in the U.S. on Sept. 20, 2018, or earlier...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

Helsinn, Chugai sales and marketing update

Chugai launched Akynzeo netupitant /palonosetron in the U.K. to prevent chemotherapy-induced nausea and vomiting (CINV). The cost of the fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and 0.5...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

The European Commission approved Akynzeo netupitant/palonosetron to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or moderately emetogenic cancer chemotherapy. The product is a fixed-dose combination of 300 mg...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Aloxi palonosetron regulatory update

The European Commission approved an expanded label for Aloxi palonosetron from Helsinn to prevent chemotherapy-induced nausea and vomiting (CINV) to include pediatric patients ages >=1 month. The selective serotonin (5-HT3) receptor antagonist is now approved...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

EMA’s CHMP recommended approval of Akynzeo netupitant/palonosetron (NEPA) from Helsinn to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or with moderately emetogenic cancer chemotherapy. The product is a...